{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-026270","form_type":"8-K","ticker":"UNCY","cik":"0001766140","company_name":"Unicycive Therapeutics, Inc.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.782412+00:00","generated_at":"2026-05-24T02:04:38.373154+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Unicycive reports FY 2024 net loss of $37.8M; OLC NDA under FDA review with PDUFA June 28, 2025","bullets":["Net loss attributable to common stockholders $37.8M or $0.56 per share, vs $31.4M ($1.28) in 2023.","Cash and cash equivalents $26.1M as of Dec 31, 2024; company expects to fund operations into 2026.","R&D expenses rose to $20.0M from $12.9M YoY; G&A expenses $12.1M vs $8.5M.","FDA accepted OLC NDA for hyperphosphatemia; PDUFA target action date June 28, 2025.","Commercial planning underway for anticipated OLC launch in late 2025 if approved."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-026270","json":"https://secwatch.observer/filing/0001213900-25-026270.json","markdown":"https://secwatch.observer/filing/0001213900-25-026270.md","text":"https://secwatch.observer/filing/0001213900-25-026270.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1766140/000121390025026270/0001213900-25-026270-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1766140/000121390025026270/ea0236324-8k_unicycive.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T02:04:38.373154+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}